VEGFA and neoplasm: Bevacizumab (rhuMAb VEGF) is a recombinant humanised anti-human VEGF monoclonal antibody, which results in a synergistic anti-tumour effect in preclinical studies when combined with fluoropyrimidines or gemcitabine (Margolin et al, 2001; az-Rubio and Schmoll, 2005; Kindler et al, 2005a).